Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · May 2020
ReviewReview article: gastrointestinal features in COVID-19 and the possibility of faecal transmission.
There is little published evidence on the gastrointestinal features of COVID-19. ⋯ Gastrointestinal symptoms are common in patients with COVID-19, and had an increased prevalence in the later stage of the recent epidemic in China. SARS-CoV-2 enters gastrointestinal epithelial cells, and the faeces of COVID-19 patients are potentially infectious.
-
Aliment. Pharmacol. Ther. · May 2020
Multicenter Study Comparative Study Observational StudyThe effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
There is no head-to-head trial comparing ustekinumab and vedolizumab in patients with Crohn's disease (CD) refractory to anti-tumour necrosis factor (anti-TNF). ⋯ This study suggests that ustekinumab is associated with a higher rate of clinical remission and treatment persistence than vedolizumab after 48 weeks of follow-up, in patients with CD refractory or intolerant to anti-TNF. The rate of SFCR was not significantly different.